CMV chemotherapy for pure squamous cell cancer of the urinary tract
| ISRCTN | ISRCTN84356042 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN84356042 |
| Secondary identifying numbers | BA08 August 1993 |
- Submission date
- 16/03/2018
- Registration date
- 03/04/2018
- Last edited
- 08/06/2023
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English summary of protocol
Background and study aims
The aim of this study is to assess the safety and activity of cisplatin, methotrexate and vinblastine (CMV) chemotherapy in patients with pure squamous cell carcinoma (SCC) of the urinary tract. SCC of the urinary tract is rare in the UK and has a poor prognosis compared with the more common type of transitional cell carcinoma (TCC). In TCC cisplatin chemotherapy has been shown to be effective and so this trial was developed to investigate the activity of cisplatin based chemotherapy in the SCC setting.
Who can participate?
Patients (any age, gender) with SCC of the urinary tract.
What does the study involve?
CMV is given as three 21-day cycles of intravenous infusions (into a vein) of methotrexate (day 1 & 8), vinblastine (day 1 & 8) and cisplatin (day 2). Folinic acid is also given 24 h after each methotrexate injection, either orally or intravenously, every 6 h for 24 h (4 times).
What are the possible benefits and risks of participating?
This study aims to find that CMV is active with few side effects in SCC, and this will then justify it being be tested in a larger group. The options for these patients can be limited. Giving a combination of 3 chemotherapies could increase side effects and the time receiving an intravenous infusion.
Where is the study run from?
Hospitals in the UK, Norway and Poland.
When is the study starting and how long is it expected to run for?
It recruited from October 1993 to February 1999
Who is funding the study?
Medical Research Council (UK)
Who is the main contact?
Gareth Griffiths
Contact information
Scientific
Southampton Clinical Trials Unit, University of Southampton, MP131, Southampton General Hospital, Tremona Road
Southampton
SO16 6YD
United Kingdom
Study information
| Study design | Phase II single-arm non-randomised open-label multicentre trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet. |
| Scientific title | MRC BA08 trial: A phase II trial of cisplatin, methotrexate and vinblastine (CMV) chemotherapy for pure squamous cell cancer of the urinary tract |
| Study acronym | BA08 |
| Study objectives | Cisplatin, methotrexate and vinblastine (CMV) chemotherapy is effective in patients with squamous cell carcinoma of the bladder |
| Ethics approval(s) | This trial was conducted in the 1990s where each participating centre approved through a Regional Ethics Committee (REC) prior to patient recruitment. |
| Health condition(s) or problem(s) studied | Squamous cell carcinoma of the bladder |
| Intervention | At UK secondary care NHS Trusts all patients received three 21-day cycles of CMV chemotherapy (cisplatin 100 mg/m2 given on day 2, methotrexate at 30 mg/m2 and vinblastine at 4 mg/m2, both given intravenously, on days 1 and 8) from their treating clinician. Folinic acid was given 24 h after each methotrexate injection at a dose of 15 mg orally or intravenously every 6 h for four doses. Cisplatin was given following a period of intravenous hydration in which at least 1 l of normal saline was given and was not administered until urine output was measured as equal to or exceeding 100 ml/h for 4 h. The administration of cisplatin was followed by 2 l further hydration with normal saline, with supplementary potassium chloride and magnesium sulphate. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase II |
| Drug / device / biological / vaccine name(s) | cisplatin, methotrexate, vinblastine |
| Primary outcome measure | The primary endpoint of the study was overall response at 9 weeks (or post-chemotherapy if chemotherapy was stopped) after the commencement of the treatment (i.e. end of 3 cycles). Definition of response was assessed by the treating clinician as follows: Complete response (CR): The disappearance of all known malignant disease. If the initial primary tumour was in the bladder, and cystectomy has not been performed, an assessment should be made of this primary tumour. If the response of the primary bladder tumour is classified as complete response (CR) on bimanual examination and cystoscopy, a deep resection biopsy should be performed at the site of the original tumour and recorded as biopsy positive or negative, i.e: CR(B-) Complete response on cystoscopic and bimanual examination. Biopsy negative. CR(B+) Complete response on cystoscopic and bimanual examination. Biopsy positive. CR(Bo) Complete response on cystoscopic and bimanual examination. Biopsy not done. Partial response (PR) : At least 50% reduction of the sum of the products of the two largest perpendicular diameters of all lesions measured at registration. In addition there can be no appearance of new lesions nor progression of any lesion. No change (NC): Less than 50% reduction of the sum of the products of the two largest perpendicular diameters of all lesions measured at registration and no lesion measured at registration has shown a 25% increase in size. Progressive disease: A 25% or more increase in the size of one or more lesions measured at registration, or the appearance of new lesions. |
| Secondary outcome measures | 1. Treatment compliance 2. Safety 3. All-cause mortality 4. Time to all-cause death These were recorded by NHS staff at the treating hospitals on Case Report Forms (CRF) at the time points of the completion of chemotherapy, first follow-up at 6 months, subsequent 6-monthly follow-ups or death. Overall survival was calculated as the time from the date of registration to date of death or censored at the time last seen if still alive. |
| Overall study start date | 01/01/1993 |
| Completion date | 01/05/2001 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | Maximum of 45 |
| Key inclusion criteria | 1. Pure squamous cell carcinoma of the urinary tract in one of the following groups: 1.1. initial presentation with T3-T4 disease 1.2. pelvic relapse after radiotherapy or surgery 1.3. nodal or metastatic disease 2. At least one site of disease assessable for response by clinical examination or imaging. One or more of the sites below can be used to assess response: 2.1. primary bladder tumour (satisfactory measurements of the primary tumour if present and measureable, must have been made by bimanual examination after transurethral resection (TUR)) 2.2. other primary tumours in the urinary tract (satisfactory measurements of the primary tumour in the urinary tract, if present and measureable, must have been made by clinical examination or appropriate imaging) 2.3. pelvic relapse after radiotherapy or surgery (at least one indicator lesion must be measurable by clinical examination or appropriate imaging) 2.4. nodal or metastatic disease (at least one indicator lesion must be measurable by clinical examination or appropriate imaging. NB: Bone metastases cannot be used as an indicator lesion. 3. Calculated glomerular filtration rate (GFR), calculated by the method of Cockcroft and Gault (1976) >50 ml/min. In patients with impaired renal function secondary to ureteric obstruction this may be relieved by ureteric stents or nephrostomies, and if the renal function then recovers the patient will be eligible. 4. White blood cell count >3.5 x 10(9)/l and platelet count >100 x 10(9)/l 5. No previous systemic treatment with chemotherapy 6. No concomitant or previous malignancy other than basal cell carcinoma of skin or carcinoma in-situ of the cervix 7. Fit to tolerate CMV |
| Key exclusion criteria | 1. Transitional cell carcinoma with squamous metaplasia, or other mixed tumours 2. Co-existing illness (e.g. cardiac failure) that may compromise administration of CMV chemotherapy |
| Date of first enrolment | 01/10/1993 |
| Date of final enrolment | 28/02/1999 |
Locations
Countries of recruitment
- England
- Norway
- Poland
- Scotland
- United Kingdom
Study participating centres
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
United Kingdom
Norway
United Kingdom
Poland
Sponsor information
Government
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, 90 High Holborn, 2nd Floor, London
London
WC1V 6LJ
United Kingdom
| Phone | +44 (0) 20 7670 4700 |
|---|---|
| enquiries@ctu.mrc.ac.uk | |
| Website | http://www.ctu.mrc.ac.uk/ |
"ROR" |
https://ror.org/03x94j517 |
Funders
Funder type
Not defined
Government organisation / National government
- Alternative name(s)
- Medical Research Council (United Kingdom), UK Medical Research Council, MRC
- Location
- United Kingdom
Results and Publications
| Intention to publish date | 01/06/2019 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | Planned publication in a high-impact peer reviewed journal. |
| IPD sharing plan | The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 16/01/2019 | 22/01/2019 | Yes | No |
| Protocol (other) | 08/06/2023 | No | No |
Editorial Notes
08/06/2023: A link to the protocol file was added.
22/01/2019: Publication reference added.
19/12/2018: The intention to publish date has been changed from 01/06/2018 to 01/06/2019.
